Merck raises revenue outlook but cuts profit guidance due to Terns Pharmaceuticals deal

Merck raised its annual revenue outlook on the back of growing sales of new drugs, but simultaneously cut its profit guidance due to charges tied to its acquisition of biotech firm Terns Pharmaceuticals. The results reflect strong sales momentum offset by rising deal-related costs.